MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, PTPI made $1,056,751 in revenue. -$1,153,933 in net income. Net profit margin of -109.20%.

Income Overview

Revenue
$1,056,751
Net Income
-$1,153,933
Net Profit Margin
-109.20%
EPS
-$0.03
Unit: Dollar
Revenue Breakdown
    • Selling, general and administrat...
    • Interest income
    • Change in fair value of warrant ...

Unit: Dollar
Income Statement
2025-09-30
2025-06-30
2024-12-31
2024-09-30
Cost of goods sold
--298,292.5 287,005
Net sales
--1,057,103 1,576,366
Gross profit
--758,810.5 1,289,361
Depreciation and amortization expense
--686,966 739,449
Research and development expense
--828,948.5 588,355
Intangible asset impairment
--741,690 -
Api asset impairment
--2,950,121 -
Selling, general and administrative
990,737 1,800,778 2,080,583.5 2,301,305
Total operating expenses
990,737 1,800,778 7,288,309 3,629,109
Loss from continuing operations
-990,737 -1,800,778 -6,529,498.5 -2,339,748
Interest expense, promissory note
--140,227.25 -
Change in fair value of derivative liability
--867,000 202,000
Change in fair value of warrant liability
-1,000 329,343 --
Interest income
67,014 88,849 88,280.5 75,817
Amount of the cost of promissory notes accounted for as interest expense for debt
---158,730
Total other income, net
68,014 -240,494 811,447 119,087
Loss before income taxes
-922,723 -2,041,272 -5,718,051.5 -2,220,661
Loss from continuing operations, net of tax
-922,723 -2,041,272 --
Gain (loss) from discontinued operations
-500,816 --
Gain from assignment of subsidiaries and vivus settlement
-6,973,302 --
Net income (loss)
-922,723 5,432,846 -5,718,051.5 -2,220,661
Preferred stock dividend and cash premiums
231,210 -519,814.5 1,051,695
Preferred stock accretion
--3,169,896.5 1,974,359
Net loss attributable to common stockholders
---9,407,762.5 -5,246,715
Net loss from continuing operations attributable to common stockholders
-1,153,933 ---
Earnings per share, basic
-0.03 -1.29 -1.22 -0.53
Earnings per share, diluted
-0.03 -1.29 -1.22 -0.53
Weighted average number of shares outstanding, basic
42,284,502 25,922,503 -4,595,931 9,829,793
Weighted average number of shares outstanding, diluted
42,284,502 25,922,503 -4,595,931 9,829,793
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss fromcontinuing operations...-$1,153,933 Preferred stock dividendand cash premiums$231,210 Net income (loss)-$922,723 Loss from continuingoperations, net of tax-$922,723 Interest income$67,014 Change in fair value ofwarrant liability-$1,000 Loss before incometaxes-$922,723 Total other income,net$68,014 Loss from continuingoperations-$990,737 Total operatingexpenses$990,737 Selling, general andadministrative$990,737

Petros Pharmaceuticals, Inc. (PTPI)

Petros Pharmaceuticals, Inc. (PTPI)